Aubagio Articles
Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed
25 March 2013
Novartis' Gilenya MS patient share growth in Europe likely driven by improved product satisfaction and efficacy-related
9 December 2012
Sanofi MS drug Aubagio gets second approval, in Australia
21 November 2012
US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch
28 September 2012
FDA thumbs up for Sanofi's MS drug Aubagio
13 September 2012
European neurologists view Rxing of Biogen Idec's BG-12, Sanofi's Aubagio and Sanofi/Bayer's Lemtrada
26 June 2012
FDA strengthens warnings on Sanofi’s Multaq; Aubagio disappoints
20 December 2011
As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst
24 October 2011
Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing
21 October 2011
Sanofi oral MS drug Aubagio shows strong efficacy in Ph III trial; plans massive Indian vaccine plant
7 October 2011
Showing 1-18 of 18 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
